The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 21, 2021
Filed:
Nov. 17, 2017
Applicant:
Viking Therapeutics, Inc., San Diego, CA (US);
Inventor:
Brian Lian, Rancho Santa Fe, CA (US);
Assignee:
Viking Therapeutics, Inc., San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/665 (2006.01); A61K 31/662 (2006.01); A61K 31/683 (2006.01); A61K 45/06 (2006.01); A61P 9/00 (2006.01); A61P 43/00 (2006.01); A61P 41/00 (2006.01); A61P 3/10 (2006.01); A61P 3/08 (2006.01); A61P 1/16 (2006.01); A61P 3/06 (2006.01); A61P 35/00 (2006.01); A61P 3/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/665 (2013.01); A61K 31/662 (2013.01); A61K 31/683 (2013.01); A61K 45/06 (2013.01); A61P 1/16 (2018.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/08 (2018.01); A61P 3/10 (2018.01); A61P 9/00 (2018.01); A61P 35/00 (2018.01); A61P 41/00 (2018.01); A61P 43/00 (2018.01);
Abstract
The present disclosure provides methods and compositions for the treatment of hepatic symptoms of glycogen storage diseases through the administration of thyroid hormone receptor agonists. The methods and compositions provided herein are useful in the treatment of hyperlipidemia, hypercholesterolemia, hepatic steatosis, cardiomegaly, hepatomegaly, hepatic fibrosis, and cirrhosis associated with glycogen storage diseases (GSD) and defects of glycogen metabolism. Said compounds may also be useful in the prevention of GSD-related hepatocellular adenoma and hepatocellular carcinoma.